Description
Product Overview: Resihance, manufactured by Bayer Pharmaceuticals Pvt. Ltd., is a potent medication containing 40 mg of regorafenib per tablet. Each pack contains tablets, offering a comprehensive and effective treatment option for patients diagnosed with certain types of advanced cancers who have exhausted other treatment options.
Active Substance: Regorafenib: Regorafenib is a multi-targeted kinase inhibitor that inhibits several protein kinases involved in tumor angiogenesis (formation of new blood vessels), oncogenesis (tumor formation), and tumor microenvironment modulation. By targeting multiple pathways, regorafenib helps suppress tumor growth and progression in various types of cancer.
Mechanism of Action: Resihance exerts its anti-cancer effects by inhibiting the activity of several protein kinases, including those involved in angiogenesis (vascular endothelial growth factor receptors), oncogenesis (Raf, RET, and KIT), and tumor microenvironment modulation (fibroblast growth factor receptors). By blocking these pathways, regorafenib disrupts tumor growth and progression, ultimately leading to tumor shrinkage and improved outcomes.
Clinical Applications: Resihance is primarily used for the treatment of:
- Metastatic Colorectal Cancer (CRC): Resihance is indicated for the treatment of metastatic CRC that has progressed after prior therapy with fluoropyrimidine-based chemotherapy, oxaliplatin, and irinotecan, as well as anti-VEGF therapy and, if KRAS wild-type, anti-EGFR therapy.
- Advanced Gastrointestinal Stromal Tumors (GIST): Resihance is also indicated for the treatment of locally advanced, unresectable, or metastatic GIST that has progressed after prior treatment with imatinib and sunitinib.
Administration and Dosage: Resihance is administered orally, typically once daily, with a low-fat meal. The recommended dosage is 160 mg (four 40 mg tablets) taken once daily for the first 21 days of each 28-day cycle. Treatment should be continued as long as patients benefit from therapy or until unacceptable toxicity occurs.
Manufacturer: Resihance is manufactured by Bayer Pharmaceuticals Pvt. Ltd., a leading global pharmaceutical company known for its commitment to quality and innovation in the field of oncology. Bayer Pharmaceuticals products undergo rigorous testing and adhere to stringent manufacturing standards to ensure safety, efficacy, and consistency.
Considerations and Side Effects: While generally well-tolerated, Resihance may cause certain side effects in some individuals, including:
- Fatigue
- Hypertension
- Hand-foot skin reaction
- Diarrhea
- Rash or dermatitis
Patients should be closely monitored for signs of adverse reactions during treatment with Resihance, and appropriate supportive care measures should be provided as needed.
Conclusion: Resihance from Bayer Pharmaceuticals Pvt. Ltd. offers a valuable treatment option for patients diagnosed with metastatic colorectal cancer and advanced gastrointestinal stromal tumors who have progressed after prior therapy. With its active substance regorafenib, Resihance helps target multiple pathways involved in tumor growth and progression, providing patients with extended survival and improved quality of life. As with any cancer medication, it is crucial to use Resihance as directed by a healthcare professional experienced in oncology and to be aware of potential side effects and complications.
Reviews
There are no reviews yet.